No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.